The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
It’s still open season for bio-piracy
Rich nations block accord on benefit-sharing rules for the world’s genetic resources
Gunning for green tech
US continues to target India over its intellectual property regime, especially in pharma, green tech sectors
Choking access to drugs
Drug prices are likely to increase as rich countries and their pharma companies squeeze Indian generics out of the market. How can India’s …
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
No climate for cleantech
Most of the clean energy innovations are with just six rich countries and hardly any technology is coming to developing nations
A lethal secrecy in trade deals
Why do democratic governments hide trade negotiations that have dire consequences for public services?
Pursuing a nationalist IPR policy
India has enough laws to protect its intellectual property rights. It is the implementation that is wanting
The pirates come ashore
German Pirate Party’s strong showing in the May elections is a sign that anti-IPR movements resonate with the people
Patent issues delaying Ebola cure
Canada's exclusive licensing rights of its Ebola patent to a US firm are holding up global development of a vaccine
New endosulfan ploy
Industry is sidestepping issues by pitching the proposed UN ban on endosulfan as the battle between generics and patented pesticides
Predatory EU pacts
EU is pushing India and Canada to sign free trade agreements that will hurt their generic drugs—and the outrage is global
What Durban did not discuss
IPRs are blocking access to mitigation and adaptation technologies. India offers a way out
Biotech industry has a new patron
Department of Biotechnology is playing venture capitalist to private companies to push biotech research in agriculture
Unholy smoke!
Inclusion of intellectual property in bilateral investment agreements is injurious to the health of developing nations
WTO gives India a clean chit
Apex trade regulator finds nothing amiss in India's intellectual property laws after exhaustive review
A people’s festival to protest CBD conference
Non-profits to represent united resolve to protect the country’s natural wealth and bio-cultural heritage from powerful economic interests
Environment ministry rapped
Parliament committee says serious inadequacies in afforestation, biodiversity programmes
Testing the CL route
Roche’s Herceptin will be a test case for government and generics industry as India readies to issue compulsory licences for life-saving drugs
EU threat to farmers
Free trade pact with EU will have a severe impact on Indian agriculture, specially the dairy sector
Fall of a premier institute
Amid funds siphoning allegations, future of National Institute of Pharma Education seems bleak
Trade barred
Countries protect their renewable energy equipment. Exporting nations see it as trade barrier
‘PESTICIDES’ IN DRUGS
Sharad Pawar’s provision for protecting test data in the Pesticides Bill could spill over into trade agreements and hit the drugs industry, too